↓ Skip to main content

Dove Medical Press

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial

Overview of attention for article published in Clinical Ophthalmology, March 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
16 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
27 Mendeley
Title
Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
Published in
Clinical Ophthalmology, March 2018
DOI 10.2147/opth.s159672
Pubmed ID
Authors

Andrea Russo, Nicolò Scaroni, Elena Gambicorti, Raffaele Turano, Francesco Morescalchi, Ciro Costagliola, Francesco Semeraro

Abstract

The aim of this study was to evaluate whether indomethacin eye drops and intravitreal ranibizumab (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV). This was a randomized, prospective pilot study of eyes with new-onset CNV. Fifty-eight patients were randomized 1:1 into a ranibizumab monotherapy (RM) group and a ranibizumab plus indomethacin (RI) group. All patients received monthly 0.5 mg IVR injections for 3 months, followed by monthly injections administered as needed. RI group patients also self-administered one drop of 0.5% indomethacin three times a day for 12 months. All patients were followed up for 12 months. At 12 months, both groups showed significant improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). The mean BCVA change from baseline to 12 months was -0.12±0.04 LogMAR and -0.20±0.04 LogMAR in the RM and RI groups, respectively, with the degree of change being significantly different between the two groups (P=0.04). At 12 months, the mean CRT in the RM group (316±41.2 µm) was significantly higher than that in the RI group (287±31.5 µm; P=0.004). The mean required number of IVR injections was 7.38±0.78 and 6.34±0.67 in the RM and RI groups, respectively (P<0.001). Compared to IVR monotherapy, combination therapy with indomethacin eye drops and IVR provides superior anatomical and visual outcomes in patients with naive CNV lesions. Moreover, topical indomethacin might reduce the frequency of IVR injections, which is very beneficial considering the chronic and expensive nature of IVR therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 22%
Student > Doctoral Student 3 11%
Student > Bachelor 3 11%
Student > Master 3 11%
Professor 2 7%
Other 4 15%
Unknown 6 22%
Readers by discipline Count As %
Medicine and Dentistry 15 56%
Biochemistry, Genetics and Molecular Biology 2 7%
Nursing and Health Professions 2 7%
Psychology 2 7%
Unspecified 1 4%
Other 0 0%
Unknown 5 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2018.
All research outputs
#2,796,255
of 25,382,440 outputs
Outputs from Clinical Ophthalmology
#196
of 3,714 outputs
Outputs of similar age
#57,072
of 344,853 outputs
Outputs of similar age from Clinical Ophthalmology
#3
of 27 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,714 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.